Affimed (NASDAQ:AFMD) Given Consensus Rating of “Buy” by Analysts

Affimed (NASDAQ:AFMD) has been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $41.67.

Several research analysts have issued reports on the stock. Laidlaw lifted their target price on shares of Affimed from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a report on Monday, April 1st. Wells Fargo & Company reduced their target price on Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, April 1st. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Affimed in a research note on Thursday, June 13th.

Affimed Price Performance

Shares of NASDAQ:AFMD opened at $5.41 on Tuesday. The business has a fifty day moving average price of $5.51 and a 200-day moving average price of $5.53. Affimed has a 1-year low of $2.23 and a 1-year high of $8.95. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.06 and a current ratio of 3.06.

Institutional Trading of Affimed

Several large investors have recently modified their holdings of AFMD. BNP Paribas Financial Markets grew its stake in shares of Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 163,162 shares during the period. Vestal Point Capital LP bought a new stake in Affimed during the fourth quarter valued at approximately $341,000. abrdn plc purchased a new stake in Affimed during the fourth quarter valued at approximately $130,000. Finally, EWA LLC bought a new position in Affimed in the fourth quarter worth approximately $89,000. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.